iX Biopharma’s iXB 401: A Breakthrough in Drug Delivery

iX Biopharma Ltd. (SG:42C) has released an update.

iX Biopharma Ltd. announced that its novel semaglutide sublingual wafer, iXB 401, achieved 20 times higher bioavailability than the oral semaglutide tablet Rybelsus in a preclinical study, suggesting a more effective and convenient treatment for diabetes and obesity. This breakthrough in drug delivery technology could lead to a more consistent and patient-friendly alternative, avoiding the need for injections and potentially reducing side effects. The study’s promising results highlight the potential for iXB 401 to enhance accessibility and sustainability in semaglutide treatments.

For further insights into SG:42C stock, check out TipRanks’ Stock Analysis page.